menu
    • menu
    [{"orgOrder":0,"company":"Mediti Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"MP-101","moa":"Metabotropic glutamate receptor 2 (mGluR2)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mediti Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mediti Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediti Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MARATHON PHARMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"MP-101","moa":"Metabotropic glutamate receptor 2 (mGluR2)","graph1":"Gastroenterology","graph2":"Phase III","graph3":"MARATHON PHARMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"MARATHON PHARMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MARATHON PHARMS \/ Undisclosed"},{"orgOrder":0,"company":"MARATHON PHARMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"MP-101","moa":"Metabotropic glutamate receptor 2 (mGluR2)","graph1":"Gastroenterology","graph2":"Phase III","graph3":"MARATHON PHARMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"MARATHON PHARMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MARATHON PHARMS \/ Undisclosed"},{"orgOrder":0,"company":"Microbiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"2,4-Dinitrophenol","moa":"Metabotropic glutamate receptor 2 (mGluR2)","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Microbiotix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbiotix \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Microbiotix \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for 2,4 Dinitrophenol

    Menu

    2,4 Dinitrophenol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Microbiotix

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Microbiotix

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2,4-Dinitrophenol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MicrobiotiX Gets IND Approval for Bacteriophage Drug MP101

                            Details : MP-101, a small molecule works as a mitochondrial proteins stimulant, shows promise in treating acute pneumonia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 27, 2025

                            Lead Product(s) : 2,4-Dinitrophenol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mediti Pharma

                            Country arrow
                            CTAD25
                            Not Confirmed

                            Mediti Pharma

                            Country arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2,4-Dinitrophenol

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

                            Details : MP-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Psychotic Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 06, 2017

                            Lead Product(s) : 2,4-Dinitrophenol

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MARATHON PHARMS

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            MARATHON PHARMS

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2,4-Dinitrophenol

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001

                            Details : MP-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 23, 2014

                            Lead Product(s) : 2,4-Dinitrophenol

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MARATHON PHARMS

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            MARATHON PHARMS

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2,4-Dinitrophenol

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in ...

                            Details : MP-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 17, 2014

                            Lead Product(s) : 2,4-Dinitrophenol

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth